[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Ernexa Therapeutics Inc (ERNA)

Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,101
  • Shares Outstanding, K 1,632
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,080 K
  • EBIT $ -12 M
  • EBITDA $ -11 M
  • 60-Month Beta 2.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-3.84
  • Number of Estimates 1
  • High Estimate $-3.84
  • Low Estimate $-3.84
  • Prior Year $-3.75
  • Growth Rate Est. (year over year) -2.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.28 +43.75%
on 08/03/26
5.51 -14.43%
on 08/25/26
+1.33 (+43.75%)
since 07/31/26
3-Month
3.28 +43.75%
on 08/03/26
9.90 -52.37%
on 07/15/26
-3.39 (-41.06%)
since 06/02/26
52-Week
3.18 +48.14%
on 05/04/26
71.50 -93.41%
on 10/29/25
-28.89 (-85.93%)
since 09/02/25

Most Recent Stories

More News
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Video webcast now available here CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator...

ERNA : 4.72 (+8.39%)
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs

Nine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?

AKTX : 9.70 (-6.46%)
ERNA : 4.72 (+8.39%)
OTLK : 0.6228 (-0.05%)
AIM : 0.2287 (-3.09%)
CNSP : 5.91 (+0.34%)
NVNO : 11.55 (+5.19%)
DARE : 0.7752 (+0.65%)
GRI : 1.9250 (+0.79%)
MBRX : 0.6831 (+5.09%)
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Video webcast now available  here CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment...

ERNA : 4.72 (+8.39%)
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance  Appointment further...

ERNA : 4.72 (+8.39%)
RFL : 2.60 (+6.56%)
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A...

ERNA : 4.72 (+8.39%)
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System Video...

ERNA : 4.72 (+8.39%)
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System

ERNA : 4.72 (+8.39%)
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances...

ERNA : 4.72 (+8.39%)
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND  ERNA-101 Plus Anti-PD-1 Achieved...

ERNA : 4.72 (+8.39%)
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling preclinical data, differentiated off-the-shelf...

ERNA : 4.72 (+8.39%)

Business Summary

Ernexa Therapeutics is developing cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa Therapeutics, formerly known as Eterna Therapeutics, is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 4.97
2nd Resistance Point 4.81
1st Resistance Point 4.58
Last Price 4.72
1st Support Level 4.19
2nd Support Level 4.03
3rd Support Level 3.80

See More

52-Week High 71.50
Fibonacci 61.8% 45.40
Fibonacci 50% 37.34
Fibonacci 38.2% 29.28
Last Price 4.72
52-Week Low 3.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.